Category Innovation/ R&D

EU Members Adopt Plan To Make Europe A Leader In Artificial Intelligence

The European Council of member states has adopted an all-encompassing plan to make Europe a global leader in artificial intelligence and integrate AI into all aspects of regional life. The plan, which comes as Europe has been identified as lagging in AI research and investment behind the United States and China, includes strong calls to ramp up investment while carefully considering AI's impact on labour and ethics.

WIPO Event: AI On All Fronts – Health, Cities, Agriculture – But Investment Needed; Europe Lagging

Artificial intelligence is with us to stay, and you can expect solutions to great challenges, but governments should be prepared to invest in education and research to keep up with the two global leaders of the field: the United States and China. This is in essence what several speakers said recently at an event held at the World Intellectual Property Organization.

Women On The Rise In Patent Filings, But Still Underutilised Potential, USPTO Says

The United States Patent and Trademark Office (USPTO) released a report on 11 February showing an increase in US patents that include at least one woman inventor from 7 percent in the 1980s to 21 percent by 2016. This is still a “small minority” of patented inventors, the report finds, and suggests that it indicates an “underutilisation” of women’s innovative potential.

TRIPS Council To Look At IP And The Public Interest, Business Interest

The World Trade Organization is the prime gathering point for the world's governments to discuss and negotiate on policies of the day. A decades-long swinging pendulum within the WTO's committee on trade and intellectual property is IP's contribution to innovation and economy and its contribution to the public interest. At its meeting this week, the committee will feature discussions on both.

Pre-Grant Opposition Filed Against Janssen’s Bedaquiline Fumarate Application In India

Tuberculosis and its variant - Drug Resistant Tuberculosis (DR-TB) - are global public health emergencies. Current treatment regimens are expensive, tedious and prolonged: the overall treatment duration is 20 months or more, requiring daily administration of drugs that are more toxic and less effective than those used to treat drug-susceptible TB. Most of the drugs for treating TB are old and are known to have severe side-effects, writes Sandeep K. Rathod.

TRIPS Debated As WHO Board Reaches Agreement On Universal Health Coverage

World Health Organization Board members agreed last week on a draft resolution for the preparation of a United Nations General Assembly high-level meeting on universal health coverage in the fall, following intensive closed consultations in which intellectual property rights played a significant role.

Current R&D Causes High Prices In Drugs; New Model Needed To Make Drugs More Affordable, Speakers Say

BANGKOK – The current research and development model may encourage innovation in medicines, but has caused drugs to become unaffordable and inaccessible for people, particularly those in low- and middle-income countries, panellists and participants at a major conference here said.

US Congressional Watchdog Launches Team For Sci/Tech Analysis

A new chapter begins. The business of technology and science has been, and will increasingly be, the business of government: with this in mind, the US Government Accountability Office (GAO) has launched a new Science, Technology Assessment and Analytics (STTA) team with the aim to expand the support to lawmakers on topics whose importance has exponentially increased in the world of today.

WIPO Sheds Light On Artificial Intelligence Patenting Trends In New Report

The World Intellectual Property Organization today released its first report on artificial intelligence showing a sharp rise in patenting activities over the last few years. WIPO Director General Francis Gurry called artificial intelligence a “game changer” during a press briefing yesterday and said WIPO hopes to spark a conversation on the issue among its member states this year. As in most other fields, leading patent offices are the United States and China.

Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues

Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly.